Finch Therapeutics Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
For the six months, revenue was USD 0.107 million compared to USD 0.715 million a year ago. Net loss was USD 69.3 million compared to USD 47.27 million a year ago. Basic loss per share from continuing operations was USD 43.21 compared to USD 29.82 a year ago.